Aligos Therapeutics (ALGS) vs NanoViricides (NNVC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NanoViricides (NNVC) has outperformed Aligos Therapeutics (ALGS) over the past year, losing 8.4% versus a loss of 46.5%. Over five years, NNVC leads with a -73.2% price change compared with -98.7% for ALGS. NanoViricides is the larger company by market cap ($33.4 million vs $33.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | NNVC |
|---|---|---|
| Share price | $5.31 | $1.31 |
| Market cap | $33.16M | $33.44M |
| 1-day change | -0.19% | -9.03% |
| YTD return | -43.03% | +15.93% |
| 1-year return | -46.53% | -8.39% |
| 5-year return | -98.66% | -73.16% |
| EPS (TTM) | $-7.41 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.69 | $2.23 |
| 52-week low | $3.98 | $0.85 |
| Distance from 52-week high | -61.21% | -41.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +886.44% | +358.02% |
| Average volume | 88.98K | 445.00K |
| Shares outstanding | 5.44M | 25.52M |
| Employees | 82 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NNVC has outperformed ALGS by 38.1 percentage points over the past year.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About NanoViricides
NNVC stock →NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies developed for the treatment of COVID infection; The latter, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ALGS vs NNVC FAQ
Which is bigger, Aligos Therapeutics or NanoViricides?
NanoViricides (NNVC) is larger, with a market capitalization of $33.44M compared with $33.16M for Aligos Therapeutics (ALGS).
Which stock has performed better over the past year, ALGS or NNVC?
NNVC returned -8.39% over the past 12 months, compared with -46.53% for ALGS (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and NanoViricides in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Aligos Therapeutics and Biotechnology: Pharmaceutical Preparations for NanoViricides.